Skip to Content

Rasburicase use while Breastfeeding

Drugs containing Rasburicase: Elitek, Fasturtec

Medically reviewed by Drugs.com. Last updated on Apr 19, 2021.

Rasburicase Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of rasburicase during breastfeeding. Because it is a large protein molecule with a molecular weight of about 34,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. However, the manufacturer recommends that breastfeeding be discontinued during rasburicase therapy and for 2 weeks after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Rasburicase

CAS Registry Number

134774-45-1

Drug Class

Breast Feeding

Lactation

Enzymes

Gout Suppressants

Urate Oxidase

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.